Senses Disorder TRIZ Cases

Fab segmentation preserves VEGF blockade while improving penetration and reducing infection risks from frequent ocular injections.

This case uses PEGylated CBS to convert homocysteine to cystathionine, improving control while reducing dietary burden.

This case uses stage-specific amniotic fluid to activate TLR4/NF-κB, rebalance macrophages, and support chronic wound repair.

This case uses defined antibody CDR sequences to bind LPA1, block dependent cell functions, and limit LPA2/LPA3 off-target effects.

Surfactant-stabilized THC emulsions address low solubility, phase separation, and discomfort in ophthalmic drug delivery.

This case uses Y436A and disulfide bridges to separate Fc variants, stabilize heterodimers, and improve bispecific antibody yield.

This case uses a triazine compound to suppress inflammatory PGE2 production while preserving other prostanoid pathways affected by NSAIDs.

This case uses a non-aqueous semifluorinated alkane vehicle to prevent anti-VEGF aggregation and preserve ocular dosing accuracy.

This case uses quaternary ammonium compounds to block sensory-neuron ion channels while minimizing effects on non-nociceptive neurons.

Thermal shock and detergent decellularization create porous fungal scaffolds with low immunogenicity and tissue-supporting structure.

This case uses Alisma, Atractylodes, citrus peels, and lotus leaf in tailored ratios to address stomach-dampness vertigo.

Multikinase inhibitors target pterygium growth and help limit recurrence after excision.

For NAION lacking effective treatment, AAV-delivered OCT4, SOX2, and KLF4 promote retinal ganglion cell rejuvenation and regeneration.

Phage-displayed scFv selection targets C1s proteolytic activity, supporting simpler antibody production for complement-mediated disorders.

Dynamic culture helps produce retinal cells with stronger survival and connectivity.

This case shows how charge and aromatic-group ratios help peptides reduce CD36 expression and protect against ischemic damage.

This case uses systemic or local plasminogen administration to inhibit retinal neovascularization, inflammation, and vascular injury.

Quaternary ammonium compounds enter large-pore channels to selectively block nociceptors and limit effects on non-nociceptive neurons.

Targeted tetrazole substitution helps PACAP resist degradation while preserving neuroprotective activity for nerve regeneration.

Blocking Notch signaling with local gamma-secretase inhibitors regenerates adult cochlear hair cells and supports hearing recovery.

Targeted changes at residues 52 and 53 improve C5-binding polypeptide stability while retaining C5 affinity and complement inhibition.

A cone-specific AAV vector uses opsin regulatory elements to restore adult visual capacity and improve color perception.

Cycloalkyl-substituted CFTR activators address limited treatment efficacy in constipation and dry eye by tuning compound structure.

This case uses tailored CFTR compounds to correct trafficking and gating defects and improve respiratory function for F508del patients.

Orbital fat-derived mesenchymal stem cells protect damaged RPE through contact or conditioned medium, supporting retinal health in AMD.

This case uses minimally invasive transtympanic FGF2 delivery to promote cochlear synaptic regeneration and improve word recognition.

A biodegradable spacer and reversible linker sustain ocular drug levels in a hydrogel, reducing dispersion and repeat injections.

This case links anti-inflammatory peptides to hyaluronic acid polymers for uveitis, sustaining concentration and limiting injection burden.

This case combines deuterated water, optimized pH, and low antagonist concentrations to preserve potency and reduce eye discomfort.

Protein degradation, aggregation, and oxidation are addressed with tuned excipients, pH, and lyophilization for stable intravitreal use.

Merotocin, thickeners, and mucoadhesive polymers support room-temperature potency for intranasal tinnitus treatment.

Solid dispersions in mini-tablets and granules support accurate dosing and bioavailability for pediatric cystic fibrosis treatment.

This case shows how modular heterocyclic structures are varied to develop mGluR7 modulators for glutamate-related disorders.

ASOs target USH2A exons 30–31 to shorten usherin, addressing the 15.6 kb sequence's mismatch with AAV packaging capacity.

This transplantation medium reduces post-thaw RPE cell loss, preserving viability and photoreceptor protection without post-thaw culturing.

This case balances 50–200 mg/ml antibody concentration with low aggregation and sub-visible particles through buffered excipients.

This composition uses selective alpha-2 agonists below 0.05% to maintain vasoconstriction while minimizing rebound hyperemia and ischemia.

This case examines bridged heterocycles that inhibit Factor B to address hemolysis and disease progression in PNH and glomerulopathies.

Specific CDR-engineered OX40 antibodies inhibit T-cell activation and lymphocyte proliferation while reducing Fc-mediated cytotoxicity.

A high-affinity ANG-2 single-domain antibody blocks TIE2, while a bispecific antibody also targets VEGF to inhibit angiogenesis.

Surrogate light chains and engineered protuberances limit immunogenicity while preserving VEGF and ANG-2 binding for eye disease treatment.

This case uses an rAAV2.7m8 vector to enable sustained aflibercept production in retinal cells and improve AMD treatment compliance.

This case combines multi-domain anti-VEGF fusion proteins with viral delivery for continuous retinal expression and durable AMD treatment.

This case modifies antibody variable regions to inhibit STAT3 phosphorylation, IL-17A, and IFN-γ release more effectively.

Benzothiophene, thienopyridine, and thienopyrimidine derivatives modulate STING to balance immune activation and disease coverage.

Decellularized Descemet's membrane supports viable limbal stem cells on a stable ocular surface.

Soluble CR1 fragments bind C3b to regulate complement while reaching Bruch’s membrane and the choriocapillaris.

Fusion-protein vesicles increase agonist density for targeted receptor clustering.

HIC, Protein A, and anion exchange chromatography reduce hamster PLBL2, helping limit immunogenicity in recombinant therapeutics.

This case combines VEGF inhibition with Tie2 activation in one bispecific antibody to reduce edema and support visual improvement.